WASHINGTON — The Food and Drug Administration has given final approval to Teva Pharmaceutical Industries Ltd.’s application to sell a generic version of Pfizer Inc.’s Viagra, the first generic Viagra approved in the U.S.

Israel-based Teva will begin selling the generic Viagra in December 2017.

The FDA has also granted Teva 180-day exclusivity for sales of generic Viagra.

Teva will sell three different strengths of the erectile dysfunction drug: 25 mg, 50 mp and 100 mg, just as Pfizer currently does.

Viagra, whose generic name is sildenafil citrate, generated $1.7 billion in revenue for Pfizer in 2015.

Teva, the world’s largest maker of generic drugs, had $19.7 billion in revenue last year.